[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531082":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":43,"collaborators":26,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":26,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":70,"whyStopped":26,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Instituto Bernabeu","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group","EXPERIMENTAL","Daily 10 mg transdermal testosterone for 21 days prior to the start of ovarian stimulation.",[13],"Drug: Transdermal Gel in Sachet Dosage Form",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","ACTIVE_COMPARATOR","No pre-treatment prior to ovarian stimulation.",[19],"Drug: No pretreatment",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Transdermal Gel in Sachet Dosage Form","Transdermal testosterone gel application prior to ovarian stimulation in the study group.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"No pretreatment","No pretreatment prior to the ovarian stimulation in the control group.",[15],[32],{"facility":5,"status":26,"city":33,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":26},"Alicante","03016","Spain","ES",{"type":38,"coordinates":39},"Point",[40,41],-0.48149,38.34517,{"lat":41,"lon":40},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Andrea Bernabeu García","Principal Investigator","100531082","phase-4-trap-study-testosterone-for-androgen-receptor-polymorphism-100531082",false,"NCT06195163","TRAP Study: Testosterone for Androgen Receptor Polymorphism","Transdermal Testosterone Pretreatment in Poor Responders With Androgen Receptor Polymorphism Undergoing ICSI: A Randomized Clinical Investigation.","TRAP","Inclusion Criteria:\n\n* Patients with low ovarian reserve according to Bologna criteria: at least two of the following three:\n\n  1. Age equal to or greater than 40 years.\n  2. Previous cycle with less than 4 oocytes retrieved.\n  3. Low ovarian reserve markers (antral follicle count \\\u003C5-7; AMH \\\u003C0.5-1.1 ng).\n* Carriers of androgen receptor polymorphism: between 22 and 24 CAG repeats.\n* Body Mass Index (BMI) less than 32.\n* Indication for in vitro fertilization.\n* Presence of both ovaries.\n* Absence of ovarian cysts.\n* Absence of endometriosis.\n* Normal karyotype and fragile X study.\n* Absence of severe male factor.\n* Semen sample from ejaculate.\n* Ability to comply with the study protocol.\n* To have given written consent.\n\nExclusion Criteria:\n\n* Non-compliance with instructions or non-formalization of informed consent.\n* Concurrent participation in another study.",true,"FEMALE","18 Years","40 Years",{"count":60,"type":61},100,"ESTIMATED","INTERVENTIONAL",[64],"PHASE4","To determine whether pretreatment with transdermal testosterone increases the number of cumulus-oocyte complexes (COCs) obtained after ovarian stimulation by more than 1.5 in patients with low ovarian reserve and androgen receptor polymorphism undergoing intracytoplasmic sperm injection (ICSI).",[67],"Fertility Disorders",[69],"ovarian stimulation; testosterone","NOT_YET_RECRUITING","2025-05-06",{"date":73,"type":74},"2025-05-09","ACTUAL",{"date":76,"type":61},"2025-09-30",{"date":78,"type":61},"2026-12-31",{"name":5,"class":6},1]